National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Perjeta (pertuzumab) is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage BC at high risk of recurrence.

Rapid Review

Commenced Completed Outcome
10/08/2015 01/09/2015 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
17/11/2015  10/05/2016 Reimbursement Not Recommended

Following NCPE assessment of the Applicant’s submission, cost effectiveness of pertuzumab (Perjeta®) (in combination with trastuzumab and chemotherapy) for this indication has not been demonstrated. Therefore it is not recommended for reimbursement.